QuantaMatrix Inc. announced that it expects to receive KRW 18.4470005 billion in funding from The Ezrah Charitable Trust, Marks And Company LLC, Mission Street Pte Limited and other investor
October 18, 2021
Share
QuantaMatrix Inc. announced a private placement of 1,604,087 common shares of par value, KRW 500 at an issue price of KRW 11,500 for gross proceeds of KRW 18,447,000,500 on October 18, 2021. The transcation will include participation from Sunghoon Kwon, CEO of the company for 267,348 shares, returning investors, The Ezrah Charitable Trust for 1,028,261 shares, Marks And Company LLC for 102,826 shares and Mission Street Pte Limited for 205,652 shares. The transaction has been approved by the board of directors of the company. The transaction is expected to close on November 5, 2021. The securities are being issued through third party allotment. The shares are subject to a hold period of one year. The total number of shares issued before capital increase are 14,872,724 shares.
QuantaMatrix Inc is a Korean-based company engaged in the development and production of in vitro diagnostics (IVD) medical devices. The Company's main products include a multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, rapid antituberculosis susceptibility testing kits, and others. In addition, the Company sells covid kits and engages in research and development of microbial diagnostic products.
QuantaMatrix Inc. announced that it expects to receive KRW 18.4470005 billion in funding from The Ezrah Charitable Trust, Marks And Company LLC, Mission Street Pte Limited and other investor